ExpreS2ion’s proprietary platform used for successful production of another transmission blocking malaria vaccine candidate
ExpreS2ion Biotech Holding AB and its affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announce that a recently published scientific article in Nature Communications on the Pfs48/45 malaria vaccine candidate adds further evidence to support that the ExpreS2 platform is an excellent tool for producing transmission blocking malaria vaccines. This is a promising class of next generation vaccines, which is developed with substantial support from the Bill and Melinda Gates foundation.The article is cowritten by researchers at the University of Oxford and ExpreS2ion, who are also engaged